P1576 - The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update

Monday, October 25, 2021

10:30 AM – 4:15 PM PT

Location: Shoreline Exhibit Hall

Has Audio

Presenting Author(s)

Diana Johnson, MS

University of California San Diego
La Jolla, CA, United States

Christina D. Chambers, PhD, MPH¹, Jane Adams, PhD², Ronghui Xu, PhD, MA¹, Diana Johnson, MS¹, Yunjun Luo, MS¹, Kenneth Lyons Jones, MD¹
¹University of California San Diego, La Jolla, CA; ²University of MA Boston, Boston, MA

Introduction: Vedolizumab is a gut-selective immunoglobulin (Ig) G1 monoclonal antibody that binds to α4β7 integrin; it is approved for the treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC) in the U.S. and elsewhere. Published studies on the effect of vedolizumab in human pregnancy are limited. Data from the ongoing Vedolizumab Pregnancy Exposure Registry (NCT02678052) in the U.S. and Canada have been collected by the MotherToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists (OTIS). This prospective observational pregnancy cohort study will enroll and analyze the outcomes of 100 vedolizumab-exposed (Vedo) participants compared to 100 disease-matched (DM) and 100 healthy comparison (HC) participants.

Methods: Pregnant women treated with vedolizumab for UC or CD with at least one dose in the first trimester were enrolled in the Vedo group. Pregnant women with UC or CD but no exposure to vedolizumab were enrolled in the DM group. Pregnant women with no exposure to any biologic during pregnancy and not diagnosed with an auto-inflammatory or other exclusionary disease were enrolled in the HC group. Data were collected from telephone interviews and maternal and pediatric medical records; live-born children were followed to one year of age with a dysmorphological examination and developmental screening. The Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ) was administered to women with CD or UC.

Results: Between December 2015 and March 2021, outcomes were collected for 295 women, 93 in the Vedo group, 104 in the DM group, and 98 in the HC group. SIBDQ mean scores were similar in the Vedo group, 5.8 (SD 1.0) and the DM group, 5.9 (SD 1.0). Preliminary descriptive outcome data are shown in Table 1. In the Vedo group 5.5% of pregnancies resulted in a fetus or infant with a major birth defect, compared to 6.8% in the DM group, and 4.7% in the HC group. No pattern of major birth defects was identified in the Vedo group.

Discussion: Preliminary data for major birth defects are reassuring. The proportion of pregnancies with vedolizumab exposure resulting in a major birth defect are within the general population range of 3-5%, are similar to proportions in the comparison groups, and did not represent a specific pattern. The Vedolizumab Pregnancy Exposure Registry is ongoing with formal statistical analysis planned once the study is completed.

	Vedo-Total (N=93)	DM-Total (N=104)	HC-Total (N=98)
Pregnancies ending with live born infant - n/N (%)	88/93 (94.6)	99/104 (95.2)	85/98 (86.7)
Spontaneous abortion – N (Left Truncation Accounted Rate^a)	3 (9.4%)	3 (6.1%)	1 (5.7%)
Termination - n/N (%)	0/93 (0.0)	0/104 (0.0)	0/98 (0.0)
Stillbirth - n/N (%)	0/93 (0.0)	1/104 (1.0)	0/98 (0.0)
Lost to follow-up (LTFU) - n/N (%)	2/93 (2.2)	1/104 (1.0)	12/98 (12.2)
Preterm delivery – N (Rate^b)	13 (15.3%)	6 (6.1%)	6 (7.3%)
Birth weight full term infants – mean g (SD)	3405.4 (437.2)	3427.9 (454.1)	3307.4 (433.6)
Number of pregnancies with major birth defects among all pregnancies excluding LTFU – n/N’ (%)	5/91 (5.5)	7/103 (6.8)	4/86 (4.7)
Serious infections in live born infants up to 1 year of age – n/N’(%)^c	3/92 (3.3)	1/99 (1.0)	1/88 (1.1)
Ages and Stages Screening at 1 year of age with concern – n/N’ (%)^c	9/48 (18.8)	19/85 (22.4)	8/56 (14.3)

^aSpontaneous abortion rate computed using Fleming-Harrington estimate at 20 weeks' gestation, accounting for left truncation because women can enroll at various times in gestation

^bComputed using Fleming-Harrington estimate at 37 weeks' gestation

^cIncludes twins

% = (n/N') * 100. N' at each category: Number of pregnancies meeting the criteria specified in the row title

Table: Table 1: Pregnancy Outcomes in the Study Cohort

Disclosures:

Christina Chambers: Amgen Inc. – Grant/Research Support. AstraZeneca – Grant/Research Support. Celgene – Grant/Research Support. Genzyme Sanofi-Aventis – Grant/Research Support. Gerber Foundation – Grant/Research Support. Gilead – Grant/Research Support. GlaxoSmithKline – Grant/Research Support. Hoffman La-Roche-Genentech – Grant/Research Support. Janssen Pharmaceuticals – Grant/Research Support. Pfizer, Inc. – Grant/Research Support. Regeneron – Grant/Research Support. Sanofi – Grant/Research Support. Sun Pharma Global FZE – Grant/Research Support. Takeda Pharmaceutical Company Limited – Grant/Research Support. UCB Pharma, USA – Grant/Research Support.

Jane Adams indicated no relevant financial relationships.

Ronghui Xu: Amgen Inc. – Grant/Research Support. Genzyme Sanofi-Aventis – Grant/Research Support. GlaxoSmithKline – Grant/Research Support. UCB Pharma, USA – Grant/Research Support.

Diana Johnson indicated no relevant financial relationships.

Yunjun Luo indicated no relevant financial relationships.

Kenneth Lyons Jones: Amgen Inc. – Grant/Research Support. Celgene – Grant/Research Support. Genzyme Sanofi-Aventis – Grant/Research Support. GlaxoSmithKline – Grant/Research Support. Hoffman La-Roche-Genentech – Grant/Research Support. Pfizer, Inc. – Grant/Research Support. Sanofi – Grant/Research Support. Takeda Pharmaceutical Company – Grant/Research Support. UCB Pharma, USA – Grant/Research Support.

Christina D. Chambers, PhD, MPH¹, Jane Adams, PhD², Ronghui Xu, PhD, MA¹, Diana Johnson, MS¹, Yunjun Luo, MS¹, Kenneth Lyons Jones, MD¹. P1576 - The Vedolizumab Pregnancy Exposure Registry: An OTIS Pregnancy Study Update, ACG 2021 Annual Scientific Meeting Abstracts. Las Vegas, Nevada: American College of Gastroenterology.